Spiljar, Martina
Kuchroo, Vijay K. http://orcid.org/0000-0001-7177-2110
Funding for this research was provided by:
National Institutes of Health (R01NS045937, R01NS30843, R01AI144166, P01AI073748, P01AI039671, P01AI056299)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Article History
Received: 2 March 2022
Accepted: 19 July 2022
First Online: 6 September 2022
Declarations
:
: V.K.K. is cofounder of Celsius Therapeutics, Tizona Therapeutics, Larkspur Biosciences and Bicara Therapeutics. His interests are reviewed and managed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies.